公开(公告)号：EP2948447B1

公开(公告)日：2016-09-21

申请号：EP14701828.7

申请日：2014-01-22

申请人： Astrazeneca AB

发明人： BARLAAM, Bernard Christophe ,  BERRY, David ,  DELOUVRIE, Benedicte ,  HARRIS, Craig Steven ,  LAMBERT-VAN DER BREMPT, Christine Marie Paul ,  OUVRY, Gilles ,  REID, Gary Patrick ,  TOMKINSON, Gary Peter

IPC分类号： C07D413/14 ,  A61K31/4245 ,  A61K31/4196 ,  A61K31/497 ,  A61P35/00

CPC分类号： C07D413/14 ,  A61K31/497 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

公开(公告)号：EP2948447A1

公开(公告)日：2015-12-02

申请号：EP14701828.7

申请日：2014-01-22

申请人： Astrazeneca AB

发明人： BARLAAM, Bernard Christophe ,  BERRY, David ,  DELOUVRIE, Benedicte ,  HARRIS, Craig Steven ,  LAMBERT-VAN DER BREMPT, Christine Marie Paul ,  OUVRY, Gilles ,  REID, Gary Patrick ,  TOMKINSON, Gary Peter

IPC分类号： C07D413/14 ,  A61K31/4245 ,  A61K31/4196 ,  A61K31/497 ,  A61P35/00

CPC分类号： C07D413/14 ,  A61K31/497 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R
1 and R
2 have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

摘要翻译： 本发明涉及式（I）（式（I））的化合物或其药学上可接受的盐，其中R 1和R 2具有本文之前在说明书中定义的任何含义; 它们的制备方法，含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。

公开(公告)号：EP2215085A2

公开(公告)日：2010-08-11

申请号：EP08841876.9

申请日：2008-10-22

申请人： AstraZeneca AB

发明人： BARLAAM, Bernard, Christophe ,  BOWER, Justin, Fairfield ,  DELOUVRIE, Benedicte ,  FAIRLEY, Gary ,  HARRIS, Craig, Steven ,  LAMBERT, Christine ,  OUVRY, Gilles ,  WINTER, Jon, James, Gordon

IPC分类号： C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  A61K31/497 ,  A61K31/4427 ,  A61P35/00

CPC分类号： C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D498/04

摘要： The invention concerns pyridine a nd pyrazine derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G 2, G3, G4, J, Ring A, n and R 3 has any of the meanings defined hereinbefo re in the description; processes for their preparation, pharmaceutical compositions containi ng them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

公开(公告)号：EP2215085B1

公开(公告)日：2011-09-07

申请号：EP08841876.9

申请日：2008-10-22

申请人： AstraZeneca AB

发明人： BARLAAM, Bernard, Christophe ,  BOWER, Justin, Fairfield ,  DELOUVRIE, Benedicte ,  FAIRLEY, Gary ,  HARRIS, Craig, Steven ,  LAMBERT, Christine ,  OUVRY, Gilles ,  WINTER, Jon, James, Gordon

IPC分类号： C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  A61K31/497 ,  A61K31/4427 ,  A61P35/00

CPC分类号： C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D498/04

摘要： The invention concerns pyridine a nd pyrazine derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G 2, G3, G4, J, Ring A, n and R 3 has any of the meanings defined hereinbefo re in the description; processes for their preparation, pharmaceutical compositions containi ng them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

公开(公告)号：EP1984330A1

公开(公告)日：2008-10-29

申请号：EP07705135.7

申请日：2007-02-07

申请人： AstraZeneca AB

发明人： ARNOULD, Jean-Claude ,  DELOUVRIE, Benedicte ,  KETTLE, Jason, Grant

IPC分类号： C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D207/48 ,  C07D211/46 ,  C07D211/96 ,  C07D401/06 ,  C07D403/06 ,  C07D409/06 ,  C07D413/06 ,  A61K31/166 ,  A61K31/18 ,  A61K31/33 ,  C07C233/87 ,  C07C311/32

CPC分类号： C07D205/04 ,  C07C233/87 ,  C07C311/04 ,  C07D207/08 ,  C07D207/12 ,  C07D207/48 ,  C07D211/46 ,  C07D211/96 ,  C07D401/06 ,  C07D403/06 ,  C07D409/06 ,  C07D413/06

摘要： The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.

摘要翻译： 本发明涉及抑制α5β1功能的化合物，其制备方法，含有它们作为活性成分的药物组合物，它们作为药物的用途，以及它们在制备用于治疗温血动物例如 人类患有显着血管生成或血管成分的疾病，例如用于治疗实体瘤。 本发明还涉及抑制α5b1的化合物，并且还表现出针对其他整联蛋白的适当选择性特征。